Navigation Links
Study Demonstrates a Safe and Cost Effective Source of Recombinant Human Transferrin
Date:6/17/2010

Optiferrin, InVitria’s recombinant human transferrin, outperforms iron chelators and provides a cost-effective cell culture media supplement that is consistent and animal component free.

Fort Collins, CO (PRWEB) June 17, 2010 -- A shift in the life science market has begun to steer cell culture scientists to re-evaluate their use of native transferrin and iron chelators to pursue recombinant alternatives. Transferrin regulates the uptake, transport and utilization of iron for cellular function, increasing cell growth and productivity. Native transferrin found in bovine or human serum has been widely used in cell culture for these added benefits. However, regulatory issues continue to arise with the use of native transferrin due to blood-borne pathogens.

A recent study published May 2010 in the Protein Expression and Purification Journal demonstrated that transferrin is efficiently produced using recombinant technology. The study, ‘Expression, Purification and Characterization of Recombinant Human Transferrin from Rice’ concluded that recombinant human transferrin can be expressed at very high levels of 10 grams per kilogram of biomass. These results were accomplished by utilizing the unique and proprietary expression system known as ExpressTec.

“Using the ExpressTec system for animal component free production of recombinant proteins has proven to not only provide safety and regulatory advantages, but also allows cost-effective sources of recombinant proteins like transferrin,” said Ning Huang, Vice President of Research and Development at InVitria.

Rice-derived recombinant human transferrin, tradename OptiferrinTM, is structurally and functionally similar to native transferrin. The results of this study show that effective and efficient methods of producing recombinant proteins enable products like Optiferrin to be cost effective and safe when compared to animal-derived transferrin.

“In this paper, we describe the unrivaled efficiency that we have achieved in a plant-based production system. These expression yields are significantly higher than other systems, which is critical to achieving commercially attractive products like Optiferrin, recombinant human transferrin,” said Deshui Zhang, InVitria Scientist and Lead Author.

InVitria has utilized Optiferrin to develop cell culture media supplements that avoid concerns about blood-borne pathogens found in animal or human serum while still optimizing performance in cell culture. Optiferrin eliminates the nuisances of serum contamination and iron chelators in mammalian cell culture by providing a well defined, high performance and animal-free solution.

“Transferrin delivers necessary iron to cells, maintains iron balance, and avoids the toxic effects of iron compounds. Optiferrin outperforms iron chelators and provides a cost effective alternative to animal-derived transferrin,” said Dr. Steve Pettit, Director of Cell Culture Research and Development at InVitria.

Optiferrin is suitable for all applications in mammalian cell culture, stem cells, regenerative medicine and biopharmaceutical drug delivery. To learn more about Optiferrin and to purchase online please visit www.Optiferrin.com.

About InVitria – InVitria.com
InVitria develops, manufactures and markets a portfolio of high performance and well defined cell culture media supplements and reagents used in bioprocessing, biopharmaceutical formulation, stem cell & regenerative medicine, life science research, medical devices and diagnostics.

For more information about InVitria’s products, please e-mail info(at)InVitria(dot)com.

All InVitria products can be purchased online at www.InVitria.com or by calling 1-800-916-8311.

###

Read the full story at http://www.prweb.com/releases/2010/06/prweb4155014.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Antiretrovirals During Breast-Feeding Shield Babies From HIV, Study Shows
2. Sex, drugs and moral goals: Penn study of reproductive strategies and recreational drug use
3. Twin study shows Mediterranean-style diet improves heart function
4. Study examines reasons patients with early stage lung cancer do not have surgery
5. UNC study helps explain why black patients with lung cancer have surgery less often than whites
6. Females May Be Naturally More Prone to Stress: Animal Study
7. Mastectomy Rates Down Overall, New Study Finds
8. Study: Getting patients to take their asthma meds
9. Study Probes Causes of Anger in Returning U.S. Soldiers
10. Study: Specific PTSD symptoms related to anger and aggressiveness among Iraq/Afghanistan veterans
11. Study: Adults take their physical activity on the road
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study Demonstrates a Safe and Cost Effective Source of Recombinant Human Transferrin 
(Date:2/18/2017)... ... February 17, 2017 , ... Butler Mobility invited Ken Matthews ... and other Butler products. Ken was impressed with the safety and reliability of ... the product on his show. This endorsement by Ken Matthews can be heard ...
(Date:2/18/2017)... ... February 18, 2017 , ... A new directory ... contact points to easily connect elderly veterans of America's armed forces to a ... It also conveys material on this year's increase in the Veterans Pension with ...
(Date:2/17/2017)... ... 2017 , ... Wells Pharmacy Network offers physicians WellsPx3, a ... non-controlled substances plus the ability to manage orders on their desktop or mobile ... electronic prescriptions, according to the Office of the National Coordinator of Health IT, ...
(Date:2/17/2017)... ... February 17, 2017 , ... Corrective Action & Preventive Action ... Webinar**, Feb. 23, 2017 — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/capamd ... preventive action (PA)? , The methods share techniques and tools but they are ...
(Date:2/17/2017)... ... February 17, 2017 , ... MAP Revenue Cycle Solutions (MAP ... has been promoted to Chief Executive Officer. , The need for maximizing ... shift that demands the transition from pay-for-service to pay-for-performance models. By delivering efficient ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... Feb. 17, 2017  Perrigo Company plc (NYSE, TASE: PRGO) today ... and Drug Administration for hydrocodone bitartrate and homatropine methylbromide oral ... Hydrocodone bitartrate and homatropine methylbromide oral solution (syrup), 5 ... relief of cough in adults and children 6 years of ... January 2017 were approximately $16 million.   ...
(Date:2/17/2017)... 17, 2017   FormFast , the leader in ... partnership with Engage , one of the largest ... . FormFast will serve as the forms automation and ... MEDITECH .  FormFast is a ... complement and enhance the electronic health record. FormFast,s technology ...
(Date:2/16/2017)... Pa. , Feb. 16, 2017 Absorption ... biologics, and medical devices, is pleased to announce that ... has been selected as a winner of the 2017 ... SmartCEO Magazine and recognizes driven executives for their ... work ethic. The awards ceremony and celebration is on ...
Breaking Medicine Technology: